Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study

Completed

• Conditions: Cervical Cancer

• Registration Number: NCT02323997
• Lead Sponsor: University of Bern

Brief Summary

This study will investigate the types of HPV in samples from women with cervical pre-cancer and cancer and gather information to help investigate the impact of HPV vaccination in Switzerland.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-12-18
• Study First Submitted QC: 2014-12-18
• Study First Posted: 2014-12-24
• Study Start: 2015-01
• Primary Completion: 2015-12
• Study Completion: 2016-05
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-12
• Last Update Posted: 2019-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 767

Inclusion Criteria

• Participant is willing and able to give informed consent for participation in the study.
• Participant is literate in German, French, Italian or English.
• Female, aged 18 years or above.
• Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix.
• Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Human papillomavirus presence and type	2 years

Trial Locations

Locations (10)

Istituto cantonale di patologia; 🇨🇭 Locarno, Switzerland

Kantonsspital Luzern; 🇨🇭 Luzern, Switzerland

Institute of Pathology Enge; 🇨🇭 Zurich, Switzerland

Institut für klinische Pathologie Medica; 🇨🇭 Zurich, Switzerland

Universitätsspital Zürich; 🇨🇭 Zürich, Switzerland

Universitätsspital Basel; 🇨🇭 Basel, Switzerland

Viollier Weintraub SA; 🇨🇭 Geneva, Switzerland

Viollier AG; 🇨🇭 Allschwil, Baselland, Switzerland

HUG - Hôpitaux Universitaires de Genève; 🇨🇭 Geneva, Switzerland

Kantonsspital Baselland; 🇨🇭 Liestal, Switzerland